Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of their body weight while reducing osteoarthritis pain.

Some patients dropped out of the trial early because they had lost so much weight.

Eli Lilly highlighted its drug's effectiveness in helping people lose weight. Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more ...